Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

J&J Bullish On OTC Drug Pricing, Consumer Regard For Its Brands

This article was originally published in The Tan Sheet

Executive Summary

Brand strength, not price cuts, drives J&J OTC product sales, says Worldwide Group Chairwoman Sandra Peterson. The firm has returned 80% of its recalled brands to store shelves and will restart Tylenol Arthritis distribution later this year, leaving one “substantive” product to re-launch.

Advertisement

Related Content

Missing CAPA Costs J&J $25 Million In Investigation Sparked By OTC Recalls
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
Lonely At The Top? Not In OTC Sector As Bayer, GSK/Novartis Challenge J&J

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS107731

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel